Innovation for progress
-
Across analytesWe develop proven technologies to stabilize, extract and analyze circulating cell-free nucleic acids, exosomes and CTCs from blood, urine and other biofluids.
-
Across fieldsWe are committed to working with researchers, pathologists and clinicians to ensure that today’s biomarker discoveries become tomorrow’s clinical breakthroughs. -
Across technologiesWe use advanced chemistries, sequencing technologies, automated platforms and interpretation tools to ensure you get meaningful results from your liquid biopsy samples. -
Across workflowsWe create robust Sample to Insight solutions to offer you a broad portfolio of tools to improve standardization, sensitivity and specificity at every step of your workflow.
Latest – Get news, updates and stories
-
Expert’s view on the advances and challenges of liquid biopsyInterview with Prof. Klaus Pantel
A Sample to Insight liquid biopsy workflow
-
Sample collection & stabilizationEnsure long-term stability of markers and eliminate analysis errors caused by transportation and storage. -
Sample preparationAchieved the highest yield and purity of circulating nucleic acids, exosomes and CTCs. -
NGS & PCR analysisFocus on relevant markers and gene expression signatures with targeted sequencing and validated PCR assays. -
Data analysisIdentify low-frequency variants and determine changes in expression with high accuracy. -
Data interpretationGenerate biological hypotheses and uncover the significance of ‘omics data to identify new targets or candidate biomarkers.
Featured – Dive deeper into liquid biopsy
-
GuideMaximize your miRNA profiling success using advanced NGS and PCR technologies. -
Webinar SeriesDiscover innovations to isolate mRNA and miRNA from urinary exosomes and other biofluids. -
VideosHear expert answers to top FAQs on liquid biopsy challenges & clinical application.
Explore our Cancer Research Hub
Accelerate your journey to insights and help conquer cancer
FAQs – Quick answers and insights
General
What is a liquid biopsy?
A quick, non-invasive procedure that limits the need for surgical biopsy. It allows biomarkers for diseases such as cancer to be discovered in biofluids such as blood and urine, allowing for better disease detection and management. We offer a comprehensive portfolio of solutions in the field of liquid biopsy solutions covering the most important analytes: circulating tumor cells, exosomes and circulating cell-free nucleic acids.
What are the advantage and challenges of liquid biopsy?
Liquid biopsies can be useful when a tissue sample is limited or hard to reach and if regular monitoring is needed. The main challenges include: detecting a low amount of analytes in a high background and a lack of standardization. To overcome these, we have developed a comprehensive portfolio of liquid biopsy solutions to meet your changing needs.
We offer:
- PAXgene technology for reliable sample collection and stabilization
- Optimized sample preparation kits for isolating ccfDNA, ccfRNA, exosomes and CTCs from various biofluids
- QIAseq solutions for NGS analysis
- Predesigned or custom arrays and panels for PCR-based analysis
- Genomics Workbench for accurate data analysis
Research
What solutions do you offer to standardize sample processing?
We offer specific solutions for collection, stabilization and isolation of exosomes, ccfDNA and ccfRNA or CTCs that reduce background and stabilize signals of interest. Our PAXgene, RNeasy and DNeasy technologies maintain superior sample quality for sensitive downstream applications such as qPCR and NGS – giving you relevant results and actionable insights.
How do I get results that are relevant for cancer research?
You need test systems that identify and measure specific biomarkers of interest relevant for the type of cancer. Using LNA-enhanced solutions and dedicated control systems in your research provides superior sensitivity and specificity with greater repeatability and reproducibility in qPCR and NGS – giving relevant results and actionable insights that work together from sample prep and screening through to validation and functional analysis will ease and accelerate the path to biomarker discoveries.
Can I isolate more than one analyte from a single plasma sample?
The QIAamp ccfDNA/RNA Kit offers co-isolation of ccfDNA and ccfRNA from the same plasma sample, providing excellent yield and quality of both analytes in the same eluate. This allows you to analyze both DNA and RNA mutations in the same liquid biopsy sample or can boost detection sensitivity to discover low-frequency tumor mutations.